Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bayer
Biotech
Bayer scraps ph.1-stage hypertension, neuropathic pain drugs
Bayer has removed a protein therapeutic for hypertension and a treatment for diabetic neuropathic pain from its phase 1 pipeline.
James Waldron
May 12, 2026 5:07am
Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect
May 6, 2026 7:20am
Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders
Apr 3, 2026 8:30am
Oryon shines out of stealth with $21M to fight Parkinson's
Mar 23, 2026 5:00am
Bayer ditches 1 AAV gene therapy from Pompe disease pair
Mar 4, 2026 9:59am
Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease
Feb 5, 2026 12:15pm
